Skip to content
Screener

EPS (Diluted) at other companies

Amgen logo
AmgenAMGN
$4.37+64.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.62-313%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
-$0.63+27.6%
CTO
Citius Oncology, Inc.CTOR
-$0.080.0%
Vor Biopharma logo
Vor BiopharmaVOR
-$5.11+1.9%

Other financials

Income statement

See full
Revenue$10.1M-9.3%
Gross profit$21.8M+2.9%
Operating income-$42.3M-16.9%
Net income-$40.6M+2.3%

Balance sheet

See full
Cash & equivalents$3.4M-46.3%
Total debt$78.6M-18.3%
Total equity$903.1M+3,830%
Total assets$1.1B+428%

Cash flow

See full
Operating cash flow-$75.8M-65.7%
CapEx$94.0K+154%
Free cash flow-$75.9M-65.7%

Valuation

See full
Market cap$1.6B+39.4%
Enterprise value$1.68B+36.4%
P/S29.4×+11.0×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-257.8%—
Net margin-287.8%+572pp
FCF margin-428.7%+1,139pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×—
Current ratio10.4×+7.8×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Nektar Therapeutics’s 10-Q, filed August 14, 2026.

Filed
Aug 13, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-349805
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total non-operating income (expense), net2,040(3,165)(1,996)(4,999)
Loss before provision (benefit) for income taxes and equity method investment(40,301)(39,395)(83,391)(85,764)
Provision (benefit) for income taxes2(188)66(136)
Loss before equity method investment(40,303)(39,207)(83,457)(85,628)
Loss from equity method investment(319)(2,386)(2,069)(6,847)
Net loss$(40,622)$(41,593)$(85,526)$(92,475)
Basic and diluted net loss per share$(1.23)$(2.95)$(2.96)$(6.57)
Weighted average shares outstanding used in computing basic and diluted net loss per share33,054,86514,087,30728,918,44514,074,545

Item 1. Condensed Consolidated Financial Statements—Unaudited:

FAQ

What is Nektar Therapeutics's EPS (diluted)?
Nektar Therapeutics (NKTR) reported EPS (diluted) of -$1.23 in Q2 2026.
How has Nektar Therapeutics's EPS (diluted) changed year-over-year?
Nektar Therapeutics's EPS (diluted) increased by 58.3% year-over-year, from -$2.95 to -$1.23.
What is the long-term trend for Nektar Therapeutics's EPS (diluted)?
Over 4 years (2021 to 2025), Nektar Therapeutics's EPS (diluted) has grown at a -66.5% compound annual growth rate (CAGR), from -$792.07 to -$10.03.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Nektar Therapeutics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude